Gideon Bollag

30.7k citations

124 papers · 14.7k indexed · 8 hit papers · h-index 51

Impact in

Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
Molecular Biology top 0.2%
- Melanoma and MAPK Pathways
- Protein Kinase Regulation and GTPase Signaling
- PI3K/AKT/mTOR signaling in cancer
- Protein Tyrosine Phosphatases

Papers in

Molecular Biology 93
- Melanoma and MAPK Pathways 37
- Protein Kinase Regulation and GTPase Signaling 23
- PI3K/AKT/mTOR signaling in cancer 14
- Protein Degradation and Inhibitors 13
- Protein Tyrosine Phosphatases 12
Oncology 33

Co-authors: Kevin Shannon Frank McCormick Suzanne SchubbertChao ZhangNeal Rosen Poulikos I. Poulikakos Kevan M. Shokat Matthew J. Hart
Journals: Cancer Research (10 papers)Blood (10 papers)Proceedings of the National Academy of Sciences (8 papers)Journal of Clinical Oncology (7 papers)Methods in enzymology on CD-ROM/Methods in enzymology (7 papers)
Partner nations: United States Germany Canada

In The Last Decade

Gideon Bollag

121 papers receiving 14.4k citations

Hit Papers

8 papers align trajectories log scale

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer 2013 · 467 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Cancer Research
2012 Nature Reviews Drug Discovery
2010 Nature
2007 Nature reviews. Cancer
2006 Nature Genetics
1998 Science
1998 Science
1990 Cell

Peers

Countries citing papers authored by Gideon Bollag

Since Specialization

Citations

This map shows the geographic impact of Gideon Bollag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gideon Bollag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gideon Bollag more than expected).

Fields of papers citing papers by Gideon Bollag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gideon Bollag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gideon Bollag. The network helps show where Gideon Bollag may publish in the future.

Co-authors

The 25 scholars most cited alongside Gideon Bollag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gideon Bollag Line = papers co-authored together Gideon Bollag links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models Nature Communications ·Jianzhao Cao, Timothy J. Purwin, Panyu Chen, Somenath Chowdhury, George L. Mellor, 内藤知佐子, Fukune Kaya, Manoela Tiago, W. D. Breaden Madden, Scott Varney, Dan A. Erkes, John M. Lamar, Claudia Capparelli, Gideon Bollag, Andrew E. Aplin	2025	0
2	Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia Clinical Cancer Research ·Catherine C. Smith, Aaron D. Viny, Evan Massi, Cyriac Kandoth, Nicholas D. Socci, Franck Rapaport, Hanna Kuczyñska, Juan S. Medina-Martínez, Elli Papaemmanuil, 秀明大窪, Henry H. Hsu, Mai H. Le, Brian L. West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah	2021	11
3	PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors Clinical and Experimental Medicine ·Yemarshet K. Gebreyohannes, Elizabeth A. Burton, Agnieszka Woźniak, Bernice Matusow, Gaston Habets, Jasmien Wellens, Jasmien Cornillie, Jack Lin, Marika Nespi, Sanjay Rajagopal, Chao Zhang, Gideon Bollag, Maria Dêbiec‐Rychter, Raf Sciot, Patrick Schöffski	2018	15
4	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo Molecular Cancer Therapeutics ·Edward J. Hartsough, Curtis H. Kugel, 貴勝賀瀬, Adam C. Berger, Timothy J. Purwin, Allison Goldberg, Michael A. Davies, Matthew J. Schiewer, Karen E. Knudsen, Gideon Bollag, Andrew E. Aplin	2017	20
5	KRAS insertion mutations are oncogenic and exhibit distinct functional properties Nature Communications ·Andres Felipe Torres Medina, Rémi Cattarin, Jessica Van Ziffle, Anagha Inguva Sheth, Gideon Bollag, Chao Zhang, Heidi Carias, David S. Dickens, Mignon L. Loh, Kevin Shannon, Ari J. Firestone	2016	11
6	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy Cancer Research ·Jemima Escamilla, Shiruyeh Schokrpur, Kushal Pratap Singh, Saul J. Priceman, Diana Moughon, Ziyue Karen Jiang, Frédéric Pouliot, Clara E. Magyar, James L. Sung, Jingying Xu, Gang Deng, Brian L. West, Gideon Bollag, Yves Fradet, Louis Lacombe, Michael E. Jung, Jiaoti Huang, Lily Wu	2015	149
7	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer Proceedings of the National Academy of Sciences ·Luping Lin, Saurabh Asthana, Elton Chan, Sourav Bandyopadhyay, Thang Tat Ngo Dinh, Victor Olivas, Jenny Yan, Katherine Baquero H. Lady, Bao‐Feng Geng, Gideon Bollag, David B. Solit, Eric A. Collisson, Charles M. Rudin, Barry S. Taylor, Trever G. Bivona	2014	73
8	CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer Cancer Research ·Jingying Xu, Jemima Escamilla, Stephen Mok, John David, Saul J. Priceman, Brian L. West, Gideon Bollag, William H. McBride, Lily Wu Hit paper breakdown →	2013	467
9	Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy Cancer Research ·Stephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag, Antoni Ribas	2013	252
10	Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents Clinical Cancer Research ·Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, Scott Kopetz	2012	235
11	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su	2011	170
12	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley P. Kolis, Sylvia Zhao, W. Jaskółowski, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su	2010	307
13	Setting up a Kinase Discovery and Development Project Current topics in microbiology and immunology ·Gideon Bollag	2010	6
14	Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proceedings of the National Academy of Sciences ·Cédric Louvet, Gregory L. Szot, Jiena Lang, Michael R. F. Lee, Zhang Y.-W., Gideon Bollag, Shirley Zhu, Arthur J. Weiss, Jeffrey A. Bluestone	2008	184
15	Biochemical and Functional Characterization of Germ Line KRAS Mutations Molecular and Cellular Biology ·Suzanne Schubbert, Gideon Bollag, Natalya Lyubynska, Hoa Nguyen, Christian P. Kratz, Martin Zenker, Charlotte M. Niemeyer, Anders Molven, Kevin Shannon	2007	70
16	Germline KRAS mutations cause Noonan syndrome Nature Genetics ·Suzanne Schubbert, Martin Zenker, Hristina Mitrova, Silke Böll, Cornelia Klein, Gideon Bollag, Ineke van der Burgt, Luciana Musante, Vera M. Kalscheuer, HENRIQUE NOGUEIRA DA GAMMA MOTA, Hoa Nguyen, Brian L. West, Kam Y. J. Zhang, Erik A. Sistermans, Anita Rauch, Charlotte M. Niemeyer, Kevin Shannon, Christian P. Kratz Hit paper breakdown →	2006	514
17	A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases Molecular Cell ·Kam Y. J. Zhang, G.L. Card, Yoshihisa Suzuki, David Artis, Daniel W. Fong, S. Gillette, A. Fletcher, Kanzow, Brian L. West, Chao Zhang, Michael V. Milburn, Sung‐Hou Kim, Joseph Schlessinger, Gideon Bollag	2004	220
18	GTPase activating proteins: critical regulators of intracellular signaling Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·H.Abasaki, Kevin Shannon, Gideon Bollag	2002	169
19	Activation of Rho GEF activity by Gα13 Methods in enzymology on CD-ROM/Methods in enzymology ·Matthew J. Hart, Telukuntla Naga Vijayeswara Sailesh, Gideon Bollag	2000	11
20	Regulation of Tiam1 Nucleotide Exchange Activity by Pleckstrin Domain Binding Ligands Journal of Biological Chemistry ·Anne Crompton, Louise H. Foley, Alexander W. Wood, Telukuntla Naga Vijayeswara Sailesh, David Stokoe, Frank McCormick, Marc Symons, Gideon Bollag	2000	46

About Gideon Bollag

Gideon Bollag is a scholar working on Molecular Biology, Oncology, Hematology, Cell Biology and Neurology, having authored 124 papers that have together received 14.7k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (37 papers), Protein Kinase Regulation and GTPase Signaling (23 papers), PI3K/AKT/mTOR signaling in cancer (14 papers), Neuroblastoma Research and Treatments (13 papers), Protein Degradation and Inhibitors (13 papers), Computational Drug Discovery Methods (12 papers), Protein Tyrosine Phosphatases (12 papers) and Cancer Mechanisms and Therapy (10 papers). The work is most often cited by research in Oncology (4.6k citations), Molecular Biology (10.1k citations), Cell Biology (1.7k citations), Neurology (1.5k citations) and Immunology (1.8k citations). Gideon Bollag has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Kevin Shannon, Frank McCormick, Suzanne Schubbert, Chao Zhang, Neal Rosen, Poulikos I. Poulikakos, Kevan M. Shokat, Matthew J. Hart, Paul C. Sternweis and William D. Singer. Their work appears in journals such as Cancer Research, Blood, Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Methods in enzymology on CD-ROM/Methods in enzymology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact